Compare OR & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OR | SYRE |
|---|---|---|
| Founded | 2014 | 2013 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 6.5B |
| IPO Year | 2014 | 2015 |
| Metric | OR | SYRE |
|---|---|---|
| Price | $29.45 | $97.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $47.00 | ★ $85.08 |
| AVG Volume (30 Days) | 1.0M | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $105.04 | N/A |
| Revenue Next Year | $20.68 | N/A |
| P/E Ratio | $55.77 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $26.86 | $14.51 |
| 52 Week High | $48.06 | $102.06 |
| Indicator | OR | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 34.44 | 63.55 |
| Support Level | N/A | $66.78 |
| Resistance Level | $37.82 | $102.06 |
| Average True Range (ATR) | 1.10 | 5.24 |
| MACD | -0.20 | 0.38 |
| Stochastic Oscillator | 14.08 | 76.48 |
OR Royalties Inc is engaged in the business of acquiring and managing precious metal and other high-quality royalties, streams and similar interests. The Company owns a portfolio of royalties, streams, offtakes, options on royalty/stream financings and exclusive rights to participate in future royalty/stream financings on various projects. Geographically, it generates majority of its income from North America and also generates some portions of income from South America, Australia, Africa and Europe.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.